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Background: The clinical efficacy and safety of a mometasone furoate/formoterol  fumarate 
(MF/F) fixed-dose combination formulation administered via a metered-dose inhaler was 
investigated in patients with moderate to very severe chronic obstructive pulmonary disease 
(COPD).
Methods: Two 52-week, multicenter, double-blind, placebo-controlled trials with identical 
study designs were conducted in current or ex-smokers (aged $40 years), and pooled study 
results are presented herein. Subjects (n = 2251) were randomized to 26 weeks of twice-daily 
treatment with MF/F 400/10 µg, MF/F 200/10 µg, MF 400 µg, F 10 µg, or placebo. After 
the 26-week treatment period, placebo subjects completed the trial and 75% of subjects on 
active treatment entered a 26-week safety extension. Coprimary efficacy variables were mean 
changes in forced expiratory volume in one second (FEV
1
), area under the curve from 0 to 
12 hours postdose (AUC
0–12 h
), and morning predose/trough FEV
1
 from baseline to the week 
13 endpoint. Key secondary efficacy variables were St George’s Respiratory Questionnaire 
scores, symptom-free nights, time-to-first exacerbation, and partly stable COPD at the week 
26 endpoint.
Results: In the 26-week treatment period, significantly greater increases in FEV
1
 AUC
0–12 h
 
occurred with MF/F 400/10 versus MF 400 and placebo at the week 13 and week 26 endpoints 
(P # 0.032). These increases were over three-fold greater with MF/F 400/10 than with MF 400. 
Also, significantly greater increases in morning predose/trough FEV
1
 occurred with MF/F 400/10 
versus F 10 and placebo at the week 13 endpoint (P , 0.05). The increase was four-fold greater 
with MF/F 400/10 than with F 10. All active treatment groups achieved minimum clinically 
important differences from baseline (.4 units) in St George’s Respiratory Questionnaire 
scores at week 26. Symptom-free nights increased by $14% in the MF/F 400/10, MF 400, 
and F 10 groups (P # 0.033 versus placebo). The incidence of exacerbations was lower in the 
MF/F groups (#33.3%) than it was in the MF, formoterol, and placebo groups ($33.8%) over 
the 26-week treatment period. The incidence of adverse events was similar in the active-treated 
and placebo-treated subjects across 26 weeks of treatment. Over the 1-year study period, there 
were no notable differences in the incidence or types of adverse events between the MF/F 400/10 
and MF/F 200/10 groups compared with the MF or formoterol groups. Differences in rates of 
individual treatment-emergent adverse events were ,3% between treatment groups. Rates of 
pneumonia were low (#2%) across all treatment groups.
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Conclusion: Patients treated with MF/F demonstrated significant improvements in lung function, health status, and exacerbation rates. 
Although significant improvements were seen with both doses, a trend showing a dose-response effect was observed in the lung function 
measurements.
Keywords: COPD, spirometry, exacerbation, inhaled corticosteroid, bronchodilator
number of exacerbations, symptoms, and health status.13 
However, inhaled corticosteroid monotherapy is not recom-
mended in COPD treatment guidelines, and inhaled corti-
costeroids are not approved for the treatment of COPD in 
the US. It is when inhaled corticosteroids are combined with 
LABAs that their effects become significant.
Concomitant therapy with an inhaled corticosteroid 
plus LABA is recommended for patients with moder-
ate to severe COPD. Recent guidelines from GOLD2 and 
the National Institute for Clinical Excellence14 recom-
mend inhaled corticosteroid/LABA combination treat-
ment for patients with FEV
1
 ,50% predicted, while a 
threshold of ,60% predicted for use was recommended 
by a joint position paper of the American Thoracic 
Society/European Respiratory Society.1 Three inhaled 
corticosteroid/LABA combination products, ie, fluticasone 
propionate/salmeterol,15–17  budesonide/formoterol,18,19 and 
beclomethasone  dipropionate/formoterol,20,21 have been 
shown to improve lung function and health status in patients 
with COPD and are approved by some regulatory agen-
cies for the maintenance treatment of COPD. Mometasone 
furoate/formoterol fumarate (MF/F) was recently approved 
for the treatment of asthma, and two Phase III trials assess-
ing the effect of MF/F in subjects with severe to very severe 
COPD symptoms were recently  completed. We present 
pooled results from the two Phase III trials of MF/F in sub-
jects with moderate to very severe COPD, which have been 
published individually, and present results in more detail.
Pooling results from these two studies of identical design 
improves the precision of the estimated treatment effect for 
MF/F, and provides a larger safety database for evaluation. 
Pooling also gives additional information on time-to-first 
COPD exacerbation, given that exacerbations occur epi-
sodically and often require larger study populations and 
extended follow-up times to discern treatment benefits on 
exacerbation rates.
Methods
The two studies were of identical design. These random-
ized, placebo-controlled, double-blind, double-dummy, 
multicenter Phase III trials evaluated twice-daily treatment 
with MF/F 400/10, MF/F 200/10, MF 400, F 10, and pla-
cebo in adults at least 40 years of age, with moderate to 
Introduction
Chronic obstructive pulmonary disease (COPD) is a chronic 
and progressive disease that has an enormous impact on 
patient health and health care resources. In the US, COPD 
affects more than 5% of the adult population and is the third 
leading cause of death. Recent estimates of total economic 
costs in the US are approximately $50 billion, with the 
direct cost of medical care approaching $30 billion.1 COPD 
is usually characterized by dyspnea and chronic productive 
cough,2 airflow obstruction that is not fully reversible, and 
a heightened inflammatory process in the lungs.2 Recurrent 
exacerbations, a hallmark of unstable COPD, further impair 
quality of life, accelerate disease progression,2 and account 
for more than 70% of the economic burden (direct costs) of 
COPD on the health care system.2
Recent guidelines published by the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) list potential treat-
ment goals, ie, relieving symptoms, preventing  progression, 
improving exercise tolerance and health status, preventing 
and treating exacerbations and complications, and reducing 
mortality.2 Bronchodilators ( anticholinergics, β
2
-agonists, 
and methylxanthines) relax airway smooth muscle and 
improve lung emptying during tidal breathing at rest and 
during exertion.3 Long-acting inhaled bronchodilators, con-
sisting of the long-acting anticholinergic, tiotropium, and 
long-acting β
2
-agonists (LABAs), including twice-daily 
salmeterol and formoterol, are recommended as monotherapy 
for patients with moderate to severe COPD,2 and have been 
shown to improve lung function, decrease symptoms, and 
reduce exacerbations.4–8 In clinical trials, formoterol has dem-
onstrated a more rapid onset of bronchodilation compared 
with salmeterol in patients with COPD.9
For patients with more advanced COPD who continue 
to have repeated exacerbations despite maximized use of 
bronchodilators, the addition of an inhaled corticosteroid is 
recommended.2 Inhaled corticosteroids have been shown to 
increase the forced expiratory volume in one second (FEV
1
) 
when added to the maintenance regimen of severe COPD 
patients10,11 and to reduce the severity12 and frequency of 
exacerbations.11 Mometasone furoate (MF) in a dry-powder 
inhaler administered at a total daily dose of 800 µg for 
12 months demonstrated significant improvements compared 
with placebo in lung function, time-to-first exacerbation, 
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very severe COPD. All treatments were administered via 
pressurized metered-dose inhaler. Subjects were enrolled at 
mutually exclusive centers across North, Central, and South 
America; Europe; Africa; and Asia (131 centers in one trial 
and 164 centers in the other trial). Both trials were registered 
on ClinicalTrials.gov (identifier numbers NCT00383435 and 
NCT00383721). A prospective statistical analysis plan for 
evaluation of pooled results was completed before unblinding 
of the two studies.
The studies were conducted in accordance with the 
principles of Good Clinical Practice and were approved by 
the appropriate institutional review boards and regulatory 
agencies. All patients gave written informed consent before 
enrollment. All subjects were monitored for COPD exacer-
bations and were provided with a COPD action plan with 
immediate availability of emergency rescue medication.
Subjects were ex-smokers or current smokers with a 
smoking history of $10 pack-years and had symptoms of 
COPD for at least 24 months. For inclusion, subjects were 
required to have a diagnosis of moderate to very severe 
COPD (based on a prebronchodilator FEV
1
/forced vital 
capacity [FVC] ratio of #70%), and post-bronchodilator 
FEV
1
 between 25% and 60% predicted normal at the screen-
ing visit. Subjects who experienced an increase in absolute 
FEV
1
 of $400 mL at the screening visit or prior to the 
baseline visit within 30 minutes after administration of four 
inhalations of albuterol (salbutamol) 360–400 µg total, or 
nebulized 2.5 mg albuterol (salbutamol) were not enrolled. 
Specific exclusion criteria were current diagnosis of asthma, 
oxygen dependence, significant ocular disease (eg, cataracts, 
glaucoma), abnormal bone density scan, visible evidence of 
oropharyngeal candidiasis, COPD exacerbation requiring 
medical intervention within 4 weeks of randomization, oral 
or parenteral corticosteroid use within 6 weeks of screening, 
and any clinically significant medical disorder.
Screening was followed by a 2-week, open-label run-in 
period, in which short-acting β
2
-agonist (SABA)/short-
acting anticholinergic fixed-dose combination treatment was 
provided for use as needed. At the baseline visit, subjects 
who qualified were randomized in a 1:1:1:1:1 ratio to twice-
daily treatment with MF/F 400/10 µg, MF/F 200/10 µg, 
MF 400 µg, F 10 µg, or placebo for 26 weeks (treatment 
period). Total doses were delivered after two inhalations 
twice daily of the following actuated doses: MF/F 200/5 µg, 
MF/F 100/5 µg, MF 200 µg, F 5 µg, or placebo. The number 
of inhalations and the treatment schedule were identical in 
each arm, for a total of four inhalations (two inhalations from 
each of two separate devices) twice daily. At the end of the 
treatment period, 75% of subjects in each active treatment 
group were randomly selected to continue their current treat-
ment, in a double-blind fashion, for an additional 26 weeks 
(safety extension, Figure 1).
Efficacy assessments
Clinical visits occurred at screening, baseline, day 1, weeks 
1, 4, 13, 26, 39, and 52, and/or end of treatment (generally 
26-week
double-blind treatment period
Day –14
Screening
Baseline
(randomization)
MF/F MDI 400/10 µg BID
MF/F MDI 200/10 µg BID
MF MDI 400 µg BID
F MDI 10 µg BID
MF/F MDI 400/10 µg BIDa
MF/F MDI 200/10 µg BIDa
MF MDI 400 µg BIDa
F MDI 10 µg BIDa
Placebo
Screening period
open-label run-in
(SABA/short-acting
anticholinergic FDC)
26-week double-blind
safety extension
Figure 1 Study design.
Notes: Total doses were delivered after two inhalations twice daily of the following actuated doses: MF/F 200/5 µg, MF/F 100/5 µg, MF 200 µg, F 5 µg, or placebo. 
a75% of each group were randomly selected to continue into the safety extension.
Abbreviations: BID, twice daily; F, formoterol; FDC, fixed-dose combination; MDI, metered-dose inhaler; MF, mometasone furoate; MF/F, mometasone furoate/formoterol 
fumarate fixed-dose combination formulation; SABA, short-acting β2-agonist.
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defined as the last week of treatment for each subject). 
 Efficacy was evaluated by pulmonary function tests at all 
visits, and serial spirometry was performed at baseline, on 
day 1, and at weeks 1, 13, and 26. Subjects were contacted by 
telephone the day before each visit and reminded of restricted 
medication washout times before the visit.  Study-provided 
SABA metered-dose inhalers and nebulizations of 2.5 mg 
albuterol (salbutamol) were to be withheld for at least 4 hours 
before visits. Washout times for vaccines (eg, influenza and 
hepatitis) and immunotherapy were one week and 24 hours, 
respectively. Investigators attempted to use one spirometer 
consistently on each subject, and the spirometer was cali-
brated at each visit. The investigator or qualified designee 
obtained three FEV
1
 and three FVC measurements at each 
visit that met the American Thoracic Society/European 
Respiratory Society guidelines for test acceptability and 
reproducibility.22 Study sites used a centralized data system 
(MasterScope CT) to capture spirometry results at each visit. 
Spirometry was performed approximately 12 hours after the 
last dose of study medication.
Patients recorded rescue medication usage (short-acting 
β
2
-agonist/short-acting anticholinergic), oral prednisone/ 
prednisolone use, number of nocturnal awakenings requir-
ing rescue medication, peak expiratory flow measurements, 
and morning and evening COPD symptom scores daily 
in e-diaries. Pulmonary health status was assessed using 
the St George’s  Respiratory Questionnaire (SGRQ). Deteriora-
tions of COPD symptoms were recorded as exacerbations and 
classified according to severity, ie, mild (managed with increased 
short-acting bronchodilator use on any two consecutive days), 
moderate (required antibiotic and/or oral steroid treatment), or 
severe (resulted in emergency treatment or hospitalization).
Primary and secondary endpoints were the same in both 
studies: to assess the contribution of formoterol, the first 
coprimary endpoint was mean FEV
1
 from 0 to 12 hours 
postdose (AUC
0–12 h
) of the change from baseline to the week 
13 endpoint. Comparators were MF/F 400/10 versus MF 
400, MF/F 400/10 versus placebo, and F 10 versus  placebo. 
Baseline FEV
1
 was the average of the two predose/trough 
FEV
1
 measurements (30 minutes before dosing and imme-
diately before dosing) at the baseline visit. To assess the 
contribution of MF, the second coprimary endpoint was 
the mean change from baseline to the week 13 endpoint in 
morning predose/trough FEV
1
. Comparators were MF/F 
400/10 versus F 10, MF/F 400/10 versus placebo, and MF 
400 versus placebo.
Key secondary efficacy outcomes included change 
from baseline in SGRQ, time-to-first COPD exacerbation, 
proportion of COPD symptom-free nights, and partly stable 
COPD. The SGRQ is a three-component questionnaire that 
measures symptoms, activity, and social and psychological 
impacts.23 Total score ranges from 0−100, with a higher 
score indicating greater disease burden. A difference in total 
score of 4 points, either from baseline or between treatment 
groups, has been established as the minimum clinically 
important difference.24 A symptom-free night was defined 
as a combined score of 0 upon awakening, prior to the use 
of study drug or rescue medication, across three domains, 
ie, wheezing, cough, and difficulty breathing. Exacerbation 
data were analyzed for the time-to-first mild, moderate, or 
severe COPD exacerbation and for the time-to-first moderate 
or severe COPD exacerbation, excluding mild events. The 
statistical analysis plan prespecified analysis of time-to-first 
mild, moderate, or severe exacerbation, whereas analysis of 
time-to-first moderate or severe exacerbation was planned 
after finalization of the statistical analysis plan but before 
unblinding of the database. Partly stable COPD was a com-
posite measure of the following outcomes: no use of oral 
steroid rescue medication; no morning or evening COPD 
weekly average symptom score greater than 2 during at least 
7 of 8 weeks; no moderate or severe COPD exacerbations; 
no unscheduled visits due to COPD worsening; and no study 
discontinuation due to treatment failure or treatment-related 
adverse event. Secondary outcomes were evaluated over the 
26-week treatment period.
Safety assessments
Subjects at all centers were monitored at each visit for 
treatment-emergent adverse events, vital signs, medica-
tion use, oropharyngeal changes, and forearm bruising. 
 Ophthalmic examinations (measurement of intraocular pres-
sure and Lens Opacities Classification System, Version III 
[LOCS III] assessments of cataracts and lens opacification), 
hypothalamic-pituitary-adrenal axis assessments (24-hour 
plasma cortisol, at selected centers), and bone mineral density 
measurements (lumbar spine, left total femur, and femoral 
neck, at selected centers), were performed at the beginning 
of the trial and at week 26 and week 52.
Statistical analysis
Statistical analyses were carried out using SAS® software 
(v 9.1; SAS Institute, Cary, NC). The total target sample size 
for analysis of pooled results was planned for 2000 patients 
(400 per treatment group). This sample size allows detection 
of a difference of 0.8 L × hour between MF/F 400/10 and 
MF 400 in change from baseline FEV
1
 AUC
0–12 h
 at the week 
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13 endpoint, with 90% power and a two-sided alpha level of 
5% significance, assuming a pooled standard deviation of 
3.6 L × hour. An 0.8 L × hour AUC converts to an average 
difference of 67 mL in FEV
1
 across a 12-hour time period. For 
the morning predose/trough FEV
1
 at the week 13 endpoint, 
the contribution of the MF 400 component was expected to 
be about 53 mL. This treatment difference can be detected at 
a power of 90% with a two-sided alpha level of 5%, assuming 
a pooled standard deviation of 230 mL.
Part of the overall effect examination was to compare 
the MF/F 200/10 and 400/10 µg doses and identify the pos-
sible added benefit of the higher dose of MF/F. Pooling the 
studies provided greater precision to the effect of each dose 
so such a comparison could be made. Furthermore, pooling 
the studies doubled the sample size and increased the power 
to detect treatment differences.
An analysis of covariance, extracting sources of varia-
tion due to treatment, country, smoking status, and baseline 
as covariates, was used to analyze responses for the change 
from baseline of the FEV
1
 AUC
0–12 h
 and the morning predose/
trough FEV
1
. Pairwise comparisons were based on least 
squares means from the model. An analysis of variance, 
extracting sources of variation due to treatment, country, and 
smoking status, was performed as a confirmatory analysis for 
these treatment comparisons. Following testing of the copri-
mary endpoints at a given dose level of MF/F, tests for the key 
secondary endpoints at the given dose level were performed 
sequentially versus placebo. Changes from baseline to the 
26-week endpoint (last observation carried forward) in SGRQ 
total score and the proportion of COPD symptom-free nights, 
were analyzed using the same analysis of covariance as speci-
fied for the lung function coprimary efficacy variables.
For the time-to-first mild, moderate, or severe COPD 
exacerbation, the log-rank test for equality of survival curves 
was used with smoking and study as covariates. A GENMOD 
model was applied to adjust for smoking and study, and 
assumed a negative binomial distribution of events. Kaplan–
Meier curves were used to display these treatment responses. 
In addition, the effect of smoking status (current versus for-
mer) on the survival curves was examined. Assessments were 
repeated for the lower dose (MF/F 200/10 µg). Hazard ratios 
were calculated for each active treatment versus placebo on 
two endpoint evaluations over 26 weeks, ie, time-to-first mild, 
moderate, or severe exacerbation, and time-to-first moderate or 
severe exacerbation. However, this required a separate analysis 
using the Cox proportional hazards method, which used the 
same covariates (smoking and study) as the log-rank test.
Results
Subject disposition and demographics
Of 5249 subjects screened, 2251 were randomized to 
 treatment. Nine subjects were enrolled at two sites simul-
taneously and were excluded from analysis. Five subjects 
were randomized but did not receive study drug. A total of 
1796 subjects completed the treatment period. The primary 
reasons for discontinuation were adverse events (4%) and 
subjects not wishing to continue for reasons unrelated to the 
assigned treatment (5%, Table 1).
Demographic characteristics and baseline lung func-
tion are presented in Table 2. Overall, 76% of subjects 
were males, 72% were white, and mean age was approxi-
mately 60 years. Demographics and disease characteristics 
were generally well balanced between treatment arms. 
However, the MF/F 400/10 group had a higher  smoking 
Table 1 Disposition of patients following randomized treatment assignment: number (%) of patients during the treatment period
Subject disposition, n (%) MF/F 200/10 μg  
BID
MF/F 400/10 μg  
BID
MF 400 μg  
BID
F 10 μg  
BID
Placebo  
BID
Total
Randomized 446 442 463 452 448 2251
Discontinued treatment period 75 (17) 75 (17) 97 (21) 87 (19) 120 (27) 454 (20)
 Adverse event 7 (2) 21 (5) 15 (3) 20 (4) 21 (5) 84 (4)
 Treatment failure 5 (1) 4 (1) 6 (1) 9 (2) 16 (4) 40 (2)
 Lost to follow-up 3 (1) 3 (1) 3 (1) 3 (1) 6 (1) 18 (1)
  Subject did not wish to continue for  
reasons unrelated to treatment
24 (5) 11 (2) 29 (6) 20 (4) 28 (6) 112 (5)
  Subject did not wish to continue for  
reasons related to treatment
6 (1) 7 (2) 13 (3) 11 (2) 16 (4) 53 (2)
Noncompliance with protocol 10 (2) 8 (2) 7 (2) 11 (2) 10 (2) 46 (2)
Did not meet protocol eligibility 14 (3) 15 (3) 20 (4) 9 (2) 19 (4) 77 (3)
Administrative 6 (1) 6 (1) 4 (1) 4 (1) 4 (1) 24 (1)
Completed treatment period 371 (83) 366 (83) 366 (79) 365 (81) 328 (73) 1796 (80)
Abbreviations: BID, twice daily; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fumarate fixed-dose combination formulation.
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 burden than the other treatment groups (51% current 
 smokers; 47 pack-years mean smoking history).
Coprimary efficacy outcomes
Improvements in FEV
1
 AUC
0–12 h
 were significantly greater for 
MF/F 400/10 compared with MF 400 (primary comparison; 
P , 0.001) and placebo (primary comparison; P , 0.001) 
at the week 13 primary endpoint (Figure 2) and all other 
endpoints. F 10 was also significantly superior to placebo 
(primary comparison) at all endpoints (P # 0.008 for all). 
These results demonstrate the significant contribution of 
formoterol. Improvements in FEV
1
 AUC
0–12 h
 were also sig-
nificantly greater for MF/F 200/10 compared with MF 400 
and placebo at all time points (P , 0.001 for all). Both doses 
of MF/F were significantly superior to F 10 at almost all 
endpoints, supporting the contribution of MF to the combina-
tion (the difference between MF/F 200/10 and F 10 was not 
significant at day 1). Improvements in FEV
1
 AUC
0–12 h
 were 
significantly greater for 400/10 compared with 200/10 at the 
week 13 endpoint (P = 0.031) and at 26 weeks (P , 0.05), 
demonstrating a dose-response relationship. Changes from 
baseline in FEV
1
 AUC
0–12 h
 are shown as standardized FEV
1
 
values in liters (FEV
1
 AUC
0–12 h
 divided by 12) in Table 3.
Serial spirometry data
Improvements in AM predose/trough FEV
1
 were  significantly 
greater for MF/F 400/10 compared with F 10 (primary 
 comparison; P # 0.008) and placebo (primary comparison; 
P , 0.001) at the week 13 primary endpoint and at all other time 
points (eg, week 26), supporting the contribution of MF to the 
combination (Table 4). No significant difference was observed 
between MF 400 and placebo (primary comparison) for change 
in morning predose/trough FEV
1
 at 13 weeks (Figure 3).
The increase in morning predose/trough FEV
1
 was not 
significantly greater with MF/F 200/10 compared with F 10 
at the week 13 endpoint. However, MF/F 200/10 was sig-
nificantly superior to placebo at all endpoints. MF/F 400/10 
was significantly superior to MF/F 200/10 at the week 13 
endpoint, consistent with the dose-response relationship seen 
in the analysis of FEV
1
 AUC
0–12 h
. MF/F 400/10 was also 
significantly superior to MF 400 at the week 13 endpoint. 
No significant improvement was seen when comparing MF/F 
200/10 and MF 400 (Figure 4).
Secondary assessments
Baseline mean total SGRQ scores were similar between 
groups (range 45.6−47.6). At the week 26 endpoint, all 
active treatment arms resulted in a clinically meaningful 
 improvement in mean total SGRQ score of more than 4 points 
(least squares mean changes from baseline were −6.82, −7.08, 
−6.54, and −5.71, for MF/F 400/10, MF/F 200/10, MF 400, 
and F 10, respectively). These changes were also signifi-
cantly greater compared with placebo (−3.05, P # 0.007, 
Figure 5). The proportion of subjects who achieved  minimum 
Table 2 Summary of demographic data and baseline characteristics
Characteristics MF/F  
200/10 μg  
BID  
(n = 446)
MF/F  
400/10 μg  
BID  
(n = 442)
MF  
400 μg  
BID  
(n = 463)
F  
10 μg  
BID  
(n = 452)
Placebo  
BID  
(n = 448)
Total randomized 
(n = 2251)
Male, n (%) 336 (75) 339 (77) 361 (78) 334 (74) 348 (78) 1718 (76)
Age (years), mean (SD) 60.4 (8.6) 59.4 (9.1) 60.2 (8.7) 59.7 (8.6) 58.8 (9.1) 59.7 (8.8)
Weight (kg), mean (SD) 71.73 (17.0) 72.41 (19.4) 73.31 (18.8) 71.90 (18.3) 72.99 (20.3) 72.47 (18.8)
Race, n (%)  
 White
 
322 (72)
 
323 (73)
 
336 (73)
 
328 (73)
 
310 (69)
 
1619 (72)
 Black or African American 11 (2) 3 (1) 6 (1) 6 (1) 11 (2) 37 (2)
 Asian 73 (16) 74 (17) 78 (17) 76 (17) 80 (18) 381 (17)
 Multiracial 39 (9) 42 (10) 43 (9) 42 (9) 47 (10) 213 (9)
 American Indian or Alaskan Native 1 (,1) 0 0 0 0 1 (,1)
Smoking status, n (%) 
 Current smokers
 
208 (47)
 
226 (51)
 
226 (49)
 
215 (48)
 
217 (48)
 
1092 (49)
 Ex-smokers 238 (53) 216 (49) 235 (51) 237 (52) 230 (51) 1156 (51)
Smoking history (pack-years), mean (SD) 40.94 (35.2) 47.39 (134.5) 40.60 (26.3) 43.32 (61.3) 41.95 (40.4) 42.82 (70.8)
FEV1 screening % reversibility, mean (SD) 8.62 (12.5) 8.54 (13.2) 9.09 (14.0) 9.60 (15.7) 9.09 (13.9) 8.99 (13.9)
FEV1 baseline (SD) 1.21 (0.43) 1.20 (0.39) 1.26 (0.44) 1.22 (0.43) 1.22 (0.44) 1.22 (0.43)
FEV1 baseline % predicted (SD) 39.06 (11.6) 38.14 (10.8) 40.26 (12.9) 39.50 (12.1) 38.55 (11.3) 39.12 (11.8)
Prebronchodilator PEF (morning)  
baseline, mean (SD)
186.48 (84.6) 185.78 (81.0) 184.99 (77.0) 182.08 (77.2) 191.93 (87.5) 186.23 (81.5)
Abbreviations: BID, twice daily; F, formoterol; FEV1, forced expiratory volume in 1 second; MDI, metered-dose inhaler; MF, mometasone furoate; MF/F, mometasone 
furoate/formoterol fumarate fixed-dose combination formulation; PEF, peak expiratory flow; SD, standard deviation.
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 clinically important difference changes from baseline 
of at least 4 points in SGRQ scores in the MF/F 400/10, 
MF/F 200/10, MF 400, F 10, and placebo groups was 52% 
(218/418), 53% (223/423), 53% (229/433), 51% (218/432), 
and 42% (173/414). The differences between proportions 
in all active treatment groups and the placebo group were 
statistically significant (P # 0.011).
The proportion of COPD symptom-free nights was simi-
lar between groups at baseline (range 0.25−0.29); baseline 
assessment included symptoms over the week prior to the first 
dose of study medication. The proportion of COPD symptom-
free nights over the 26-week treatment period increased in 
all treatment groups, with a least squares mean change from 
baseline of 0.15, 0.13, 0.14, 0.14, and 0.10 in the MF/F 
400/10, MF/F 200/10, MF 400, F 10, and placebo groups, 
respectively. Compared with placebo, significantly greater 
improvements were seen in the MF/F 400/10, MF 400, and 
F 10 arms (P # 0.033) but not in the MF/F 200/10 arm.
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Figure 2 Change from baseline in FEV1 AUC0–12 h (L × hour) at week 13 (last observation carried forward).
Notes: *P , 0.001 versus placebo; †P , 0.001 versus MF 400; ‡P # 0.011 versus F 10; ¶P = 0.031 versus MF/F 200/10.
Abbreviations: AUC0–12 h, area under the curve from 0 to 12 h postdose; FEV1, forced expiratory volume in 1 second; F, formoterol; MF, mometasone furoate; 
MF/F, mometasone furoate/formoterol fumarate fixed-dose combination formulation.
Table 3 Change from baseline in FEV1 AUC0–12 h in all randomized subjects
MF/F 200/10 μg BID MF/F 400/10 μg BID MF 400 μg BID F 10 μg BID Placebo
n LS meana n LS mean n LS mean n LS mean n LS mean
Change from BL
Day 1 434 1.452*,† 426 1.553*,†,‡ 444 0.189 437 1.197*,† 421 0.024
Week 1 408 1.836*,†,‡ 401 1.936*,†,‡ 413 0.641* 422 1.281*,† 389 0.049
Week 13 388 1.621*,†,‡ 374 2.218*,†,‡ 392 0.556* 377 1.070*,† 346 −0.006
Week 13 EPb 437 1.591*,†,‡ 430 2.063*,†,‡ 453 0.648* 444 1.038* 432 0.123
Week 26 336 1.365*,†,‡ 330 1.879*,†,‡ 335 0.316 331 0.713* 281 −0.010
Week 26 EPb 438 1.376*,†,‡ 430 1.809*,†,‡ 454 0.513* 444 0.790* 432 0.040
Notes: aLS means are obtained from an analysis of covariance model with treatment, strata (ex-smoker or current smoker), country and study as factors and baseline 
as a covariate; blast post-baseline non-missing result through the 13-week or 26-week evaluation carried forward. *P , 0.032 versus placebo; †P , 0.029 versus MF 400; 
‡P , 0.05 versus F 10.
Abbreviations: BID, twice daily; BL, baseline; EP, endpoint; F, formoterol; FEV1, forced expiratory volume in 1 second; LS, least squares; MF, mometasone furoate; 
MF/F, mometasone furoate/formoterol fumarate fixed-dose combination formulation.
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In the evaluation of pooled data for subjects with partly 
stable COPD over the last 8 weeks of treatment, no statisti-
cally significant differences were observed between treat-
ments at the week 26 endpoint for the proportion of subjects 
with partly stable COPD. In the MF/F 400/10, MF/F 200/10, 
MF 400, F 10, and placebo groups, the proportions of subjects 
with partly stable COPD at endpoint were 39.5%, 44.3%, 
38.1%, 42.0%, and 38.7%, respectively.
COPD exacerbations
The percentage of subjects who experienced at least one mild, 
moderate, or severe COPD exacerbation across the 26-week 
treatment period in the MF/F 400/10, MF/F 200/10, MF 400, 
F 10, and placebo groups were 31.7%, 33.3%, 33.8%, 39.1%, 
and 39.4%, respectively. Based on the log-rank test for equality 
of survival curves (adjusted for smoking), MF/F 400/10, MF/F 
200/10, and MF 400 were superior to placebo (P # 0.038). 
MF/F 400/10 and MF/F 200/10 were also superior to F 10 
(P # 0.049, Figure 6). When only moderate and severe exac-
erbations were considered, the combination arms separated 
more distinctly from the other treatment arms. The percentage 
of subjects with moderate or severe COPD exacerbations was 
12.1% with MF/F 400/10 and 20.7% with placebo. Based 
on adjusted survival curves, MF/F 400/10 was superior to 
Table 4 Change from baseline in morning predose/trough FEV1 in all randomized subjects
MF/F 200/10 μg BID MF/F 400/10 μg BID MF 400 μg BID F 10 μg BID Placebo
n LS meana n LS mean n LS mean n LS mean n LS mean
Change from BL
Week 1 412 0.061*,†,‡ 417 0.070*,†,‡ 435 0.011* 434 0.027* 413 −0.020
Week 4 418 0.075* 409 0.091*,†,‡ 434 0.054* 418 0.043 407 0.019
Week 13 408 0.061* 396 0.112*,†,‡,§ 412 0.025* 399 0.025* 378 −0.025
Week 13 EPb 431 0.060* 428 0.104*,†,‡,§ 451 0.026 443 0.026 428 −0.010
Week 26 352 0.063*,‡ 342 0.102*,†,‡ 347 0.031* 341 −0.002 310 −0.018
Week 26 EPb 431 0.065*,‡ 428 0.090*,†,‡ 451 0.036* 443 0.008 428 −0.004
Notes: aLeast squares means are obtained from an analysis of covariance model with treatment, smoking strata (ex-smoker or current smoker), country, and study as factors 
in addition to baseline as a covariate; blast post-baseline non-missing result through the 13-week or 26-week evaluation carried forward. *P , 0.05 versus placebo; †P # 0.039 
versus MF 400; ‡P # 0.025 versus F 10; §P , 0.02 versus MF/F 200/10.
Abbreviations: AM, morning; BID, twice daily; BL, baseline; EP, endpoint; F, formoterol; FEV1, forced expiratory volume in 1 second; LS, least squares; MF, mometasone 
furoate; MF/F, mometasone furoate/formoterol fumarate fixed-dose combination formulation.
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Figure 3 Morning predose/trough FEV1 at week 13 endpoint (last observation carried forward).
Notes: *P , 0.001 versus placebo; †P , 0.001 versus MF 400; ‡P , 0.001 versus F 10; ¶P = 0.018 versus MF/F 200/10.
Abbreviations: FEV1, forced expiratory volume in 1 second; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fumarate fixed-dose 
combination formulation.
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MF 400, F 10, and placebo (P # 0.030); MF/F 200/10 was 
superior only to F 10 and placebo (P # 0.009).
Pooled exposure-adjusted exacerbation rates showed 
that the incidence of exacerbations was lower in the MF/F 
and MF groups than it was in the formoterol group over the 
52-week study period. The calculation of exposure-adjusted 
rates, expressed as events per patient-years, adjusts for the 
varying duration of exposure across treatments. The pooled 
exacerbation rates for the MF/F 400/10, MF/F 200/10, MF 
400, and F 10 groups over the study period were 0.33, 0.34, 
0.35, and 0.42 patient-years, respectively. Treatment advan-
tages were marginally significant for MF/F 400/10 versus 
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Figure 4 Changes from baseline in morning predose/trough FEV1 over the study period (last observation carried forward).
Note: Subjects randomized to placebo were only enrolled up to week 26.
Abbreviations: F, formoterol; FEV1, forced expiratory volume in 1 second; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose combination 
formulation.
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Figure 5 St George’s Respiratory Questionnaire total score change from baseline at week 26 endpoint.
Notes: *P , 0.001 versus placebo; †P = 0.007 versus placebo.
Abbreviations: F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fumarate fixed-dose combination formulation; SGRQ, St George’s 
Respiratory Questionnaire.
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F 10 (P = 0.052) and MF/F 200/10 versus F 10 (P = 0.063) 
adjusting for smoking and study.
Using the Cox proportional hazard model, pooled hazard 
ratios for mild, moderate, or severe exacerbations with MF/F 
400/10, MF/F 200/10, MF 400, and F 10 versus placebo were 
0.761, 0.782, 0.825, and 0.972, respectively. The pooled 
hazard ratios for moderate or severe exacerbations with MF/F 
400/10, MF/F 200/10, MF 400, and F 10 versus placebo were 
0.571, 0.611, 0.828, and 0.957, respectively.
Safety
All four active treatments were well tolerated. During 
the 26-week treatment period, the percentage of subjects 
reporting any treatment-emergent adverse event was 
similar across the f ive treatment groups (31.8% with 
MF/F 200/10 to 36.2% with placebo). The most com-
monly reported treatment-emergent adverse events were 
headache, COPD, nasopharyngitis, upper respiratory tract 
infection, and hypertension (Table 5). COPD was reported 
as an adverse event if the subject had COPD symptoms 
or an exacerbation the investigator judged to have a clear 
temporal relationship with treatment administration. The 
incidence of COPD as a t reatment-emergent adverse event 
was reported by 63  subjects (2.8%), ranging from 1.6% 
in the MF/F 200/10 group to 4.2% in the placebo group. 
During the treatment period, 164 subjects reported serious 
adverse events. COPD was by far the most frequent severe 
adverse event, reported by 15, 7, 12, 12, and 20 subjects in 
the MF/F 400/10, MF/F 200/10, MF 400, F 10, and placebo 
groups, respectively. Pooled results for treatment-emergent 
adverse events over the 52-week study period demonstrated 
that 17.0%–19.0% of subjects across the active treatment 
groups reported mild adverse events, whereas 15.4%–17.7% 
of subjects reported moderate adverse events. No more than 
7.0% of subjects in any group reported severe treatment-
emergent adverse events.
Treatment-related oral candidiasis, including esophageal 
and oropharyngeal, was reported by 19 subjects overall 
(0.8%) during the treatment period. Pneumonia, including 
lobar and viral pneumonia, was infrequent, occurring in 
nine (2.0%), five (1.1%), five (1.1%), six (1.3%), and three 
(0.7%) subjects in the MF/F 400/10, MF/F 200/10, MF 400, 
F 10, and placebo groups. During the 52-week study period, 
fewer than 6% of subjects in any treatment group reported 
any single treatment-emergent adverse event of any severity. 
Across the treatment groups, more subjects reported mild 
treatment-emergent adverse events than treatment-emergent 
adverse events of greater severity.
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Figure 6 Time-to-first mild, moderate or severe COPD exacerbation over the 26-week treatment period: Kaplan–Meier survival curves by treatment (all randomized subjects).
Abbreviations: F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fumarate fixed-dose combination formulation.
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No abnormal, clinically relevant trends in laboratory 
values, vital signs, or electrocardiogram measurements 
were observed in the two studies. No clinically relevant 
trends or statistically significant treatment differences were 
observed for plasma cortisol levels, bone mineral density 
 measurements, ocular changes, or forearm bruising.
Discussion
In this prospectively designed pooled analysis of two large, 
placebo-controlled Phase III studies in subjects with moderate 
to very severe COPD, significantly greater improvements in 
lung function were seen for twice-daily treatment using MF/F 
compared with placebo. Both dosing levels (MF/F 400/10 and 
MF/F 200/10) demonstrated significant improvements in both 
coprimary efficacy variables (morning predose/trough FEV
1
 
and FEV
1
 AUC
0–12 h
) compared with placebo at all assessments 
from day 1 through week 26. In comparing the two combina-
tion regimens, the higher dose was associated with statistically 
greater improvements in both coprimary  endpoints, demon-
strating a significant dose-response relationship. Significant 
benefits in health status, night-time symptoms, and COPD 
exacerbation rates were also demonstrated with both MF/F 
doses. Both MF/F doses were well tolerated relative to their 
individual components and placebo.
Contribution of individual components
Although inhaled corticosteroids are frequently prescribed 
to reduce symptoms, improve health status, and decrease 
exacerbations,25 inhaled corticosteroid monotherapy is not 
recommended in COPD treatment guidelines1 and is also not 
approved for treatment of COPD in the US.25 However, MF 
has been shown to improve lung function and health status 
and reduce exacerbations significantly over 1 year.13
Our results show that MF contributes to the efficacy of 
MF/F, as demonstrated by significantly greater improve-
ment in morning predose/trough FEV
1
 with MF/F 400/10 
compared with F 10. These differences were significant at 
day 1 and continued through 26 weeks. Improvements were 
not significantly different between inhaled corticosteroid 
monotherapy, MF 400, and placebo at the week 13 primary 
endpoint, but were significant at all other endpoints. Like-
wise, significantly greater improvements in FEV
1
 AUC
0–12 h
 
for MF/F 200/10 and 400/10 compared with F 10 across all 
time points from week 1 through week 26 demonstrate the 
contribution of MF to the combination.
LABAs are recommended for long-term management of 
COPD, and patients treated with formoterol, an approved 
COPD monotherapy in the US, demonstrate rapid onset of 
bronchodilation and sustained improvements in lung function 
with twice-daily dosing.4,26,27 Our results show that formot-
erol contributes to the efficacy of combination therapy, as 
demonstrated by the significantly greater improvement in 
FEV
1
 AUC
0–12 h
 with MF/F 400/10 compared with MF 400. 
Improvements in FEV
1
 AUC
0–12 h
 were also significantly 
greater with F 10 than with placebo.
Health status, assessed using the SGRQ, was signifi-
cantly improved with both combination doses. SGRQ has 
been widely utilized to assess health status in inhaled 
corticosteroid-LABA combination trials.11,18,19,28–30 In studies 
up to 1 year, a change from baseline of more than 4 points 
has been reported with some combination regimens18,19 but 
not others.18,19,29 Rennard et al and Tashkin et al compared 
budesonide/ formoterol 160/9 µg twice daily with budes-
onide/formoterol 320/9 µg twice daily. In both studies, the 
change from baseline was .4 points in the lower-dose groups 
but ,4 points in the higher-dose groups. In the  current 
Table 5 Summary of treatment-emergent adverse events $2% incidence (all randomized subjects) during the treatment period
Adverse events,  
n (%)
MF/F 200/10 μg BID  
(n = 446)
MF/F 400/10 μg BID  
(n = 442)
MF 400 μg BID  
(n = 463)
F 10 μg BID  
(n = 452)
Placebo  
(n = 448)
Patients reporting any adverse  
event, n (%)
142 (31.8) 157 (35.5) 156 (33.7) 163 (36.1) 162 (36.2)
Nasopharyngitis 9 (2.0) 13 (2.9) 14 (3.0) 12 (2.7) 12 (2.7)
Influenza 10 (2.2) 4 (0.9) 9 (1.9) 8 (1.8) 7 (1.6)
Upper respiratory tract infection 9 (2.0) 16 (3.6) 10 (2.2) 8 (1.8) 16 (3.6)
Headache 15 (3.4) 13 (2.9) 17 (3.7) 19 (4.2) 22 (4.9)
Chronic obstructive pulmonary  
diseasea
7 (1.6) 15 (3.4) 11 (2.4) 11 (2.4) 19 (4.2)
Hypertension 15 (3.4) 7 (1.6) 8 (1.7) 13 (2.9) 8 (1.8)
Back pain 6 (1.3) 3 (0.7) 6 (1.3) 9 (2.0) 5 (1.1)
Note: aIf COPD exacerbation met criteria for a severe adverse event (eg, life-threatening, required hospitalization or prolonged hospitalization) it was recorded as an 
adverse event.
Abbreviations: BID, twice daily; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fumarate fixed-dose combination formulation.
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analysis, both MF/F doses resulted in clinically relevant 
improvements (.4 point change from baseline); however, the 
lower-dose group additionally demonstrated a change of .4 
points compared with placebo. Effects such as these were not 
seen with higher-dose and lower-dose combinations in other 
studies,11,18,19,28–30 which did not evaluate MF/F. MF/F 400/10 
also demonstrated a significant improvement over placebo 
in the proportion of COPD symptom-free nights; however, 
the lower-dose combination did not show a significant dif-
ference over placebo.
The primary modes of action of LABAs and inhaled corti-
costeroids are distinct, namely bronchodilation and suppression 
of airway inflammation.31 However, the following potential 
synergistic effects between the two classes have been suggested 
based on in vitro studies: inhaled corticosteroids enhance 
β
2
-adrenoceptor expression, which may prevent development 
of tolerance to β
2
-agonists with prolonged use; and LABAs 
amplify the anti-inflammatory effects of corticosteroids by 
accelerating nuclear translocation of the glucocorticoid receptor 
complex and enhancing transcription and expression of steroid-
inducible genes in proinflammatory cells.32,33 Our analysis 
supports a synergistic effect of mometasone and formoterol 
on lung function. Based on morning predose/trough FEV
1
 
measurements, MF/F 400/10 had a treatment effect (change 
from baseline) of 104 mL at the primary endpoint (13 weeks), 
which was greater than the summed treatment effects of MF and 
F (26 mL and 26 mL, respectively). Similarly, for standardized 
FEV
1
 AUC
0–12 h
, the treatment effect of MF/F 400/10 (172 mL) 
was greater than the sum of the treatment effects of MF 400 
and F 10 (87 mL and 54 mL, respectively).
Although these trials were not designed to compare the 
efficacy of the two MF/F combination doses, the results 
clearly suggest greater benefits with MF/F 400/10 than with 
MF/F 200/10. Improvements in lung function (morning 
predose/trough FEV
1
 and FEV
1
 AUC
0–12 h
) were significantly 
greater with MF/F 400/10 compared with MF/F 200/10 at 
the week 13 endpoint, and were numerically greater at all 
assessment times.
Dose-dependent responses were also seen in the percent-
age of subjects who developed exacerbations of COPD symp-
toms and in reductions in night-time symptoms, although the 
differences between the higher-dose and lower-dose groups 
were not statistically significant.
Pooled exposure-adjusted exacerbation rates were lower 
in the MF/F groups than they were in the formoterol group, 
although the differences were marginally significant. In 
addition, compared with placebo, pooled hazard ratios 
for mild, moderate, or severe exacerbations were reduced 
19% more in the MF/F 200/10 group and 21% more in 
the MF/F 400/10 group than they were in the formoterol 
group.  Furthermore, pooled hazard ratios for moderate or 
severe exacerbations were reduced 35% more in the MF/F 
200/10 group and 39% more in the MF/F 400/10 group than 
they were in the formoterol group.
Safety
MF/F was well tolerated at both dosing levels. The 
occurrence of total adverse events and treatment-related 
adverse events was similar across active treatment groups. 
A dose-related increase in the risk of pneumonia has been 
associated with the use of inhaled corticosteroid-containing 
regimens in COPD patients.34,35 We found that the incidence 
of pneumonia was low overall, although slightly higher in 
the MF/F 400/10 group than in other groups. Other studies 
have also reported an increase in oral candidiasis in inhaled 
corticosteroid-LABA trials.16,18 Oral candidiasis was very 
infrequent, with similar rates seen in the combination 
arms compared with non-MF-containing arms (F 10 and 
placebo). There was also an absence of any significant 
demonstrable adverse effect on bone density or ocular 
changes. While these data indicate MF/F was safe over 
the course of 1 year, longer trials should be conducted to 
confirm long-term safety.
Conclusion
In this pooled analysis of two large, 1-year, placebo-
controlled clinical trials, patients treated with the MF/F 
pressurized metered-dose inhaler combination demonstrated 
significant improvements in lung function, health status, and 
exacerbation rates at the two doses investigated. Although 
significant improvements were seen at both combination 
doses, the higher dose was significantly more effective 
in improving lung function. A dose-response effect was 
observed in the lung function measurements.
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